Cytokine release during long-term extracorporeal circulation in an experimental model.
The objective of this study was to determine the degree of leukocyte activation, as measured by cytokine release, in circulating blood during experimental extracorporeal circulation. Complete in vitro extracorporeal membrane oxygenation (ECMO) circuits were used, and 9 experiments were performed. Whole blood stored at 37 degrees C was used as the control. Blood samples were withdrawn before the start of perfusion and at 24 h of perfusion. Statistically significant releases of interleukin (IL)-1beta, IL-8, and IL-1 receptor antagonist were observed in the perfusion circuits compared to both the control blood and baseline values. Also, increases in plasma tumor necrosis factor (TNF)alpha and IL-6 were seen after 24 h of perfusion although these changes did not reach statistical significance. These results indicate that extracorporeal circulation induced leukocyte activation and cytokine release. These reactions might, as an additional trauma, deteriorate the situation in an already severely ill patient. A search for methods to counteract this untoward activation seems warranted.
Adrian
K
K
Department of Pediatrics, Sahlgrenska University Hospital, Göteborg, Sweden.
Mellgren
K
K
Skogby
M
M
Friberg
L G
LG
Mellgren
G
G
Wadenvik
H
H
D000328:Adult; D000925:Anticoagulants / Q000097:blood; D001772:Blood Cell Count; D002634:Chemotaxis, Leukocyte / Q000502:physiology; D016638:Critical Illness; D016207:Cytokines / Q000097:blood*; D004867:Equipment Design; D005112:Extracorporeal Circulation / Q000295:instrumentation / Q000379:methods; D006454:Hemoglobins / Q000032:analysis; D006493:Heparin / Q000097:blood; D006801:Humans; D007375:Interleukin-1 / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D016209:Interleukin-8 / Q000097:blood; D007958:Leukocyte Count; D007962:Leukocytes / Q000502:physiology; D009504:Neutrophils / Q000166:cytology; D010106:Oxygenators; D010976:Platelet Count; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis
D000925:Anticoagulants; D016207:Cytokines; D006454:Hemoglobins; D007375:Interleukin-1; D015850:Interleukin-6; D016209:Interleukin-8; D017472:Receptors, Interleukin-1; D014409:Tumor Necrosis Factor-alpha; D006493:Heparin